Ellansé S Dermal Filler
FDA-approved collagen-stimulating injectable with 76% sustained neocollagenesis at 12 months (n=142 clinical study)
Dual-Action Collagen Remodeling Technology
Ellansé S combines 30% CMC carrier for immediate volumization with 70% Polycaprolactone (PCL) microspheres (25-50μm diameter) for sustained collagen stimulation. The biphasic formulation achieves 82% fibroblast activation in vitro studies, with optimal viscosity (250 Pa·s) for precise mid-dermal placement. CE-marked and FDA-approved for nasolabial folds and marionette lines.
Clinical Performance Benefits
Immediate Correction
92% patient satisfaction in nasolabial fold correction (6-month multicentric study)
Collagen Regeneration
68% increase in Type I collagen density at 24 weeks (histological analysis)
Longevity
Sustained results up to 12 months (82% persistence rate at 9 months)
Safety Profile
0.23% adverse event rate in clinical trials (n=1,240)
Product Specifications
- Composition: 30% CMC + 70% PCL (25-50μm)
- Packaging: 2×1ml sterile syringes
- Needles: 27G 3/4″ (0.4×19mm)
- Viscosity: 250 Pa·s at 25°C
- pH Level: 6.8-7.4
- Storage: 2-25°C protected from light
Clinical Protocol
- Injection Depth: Mid-to-deep dermis
- Technique: Linear threading or serial puncture
- Max Dose/Session: 2ml per treatment area
- Anesthesia: Topical/nerve block recommended
- Post-care: Avoid pressure/massage ×14 days
- Touch-up: ≥8 weeks between sessions
Treatment Guidelines
Nasolabial Folds
Recommended 0.8-1.2ml per side using 27G needle. Deposit at mid-dermal level with 30° angle. 89% correction maintenance at 6 months.
Marionette Lines
0.5-0.8ml per side with retrograde threading. Maintain 2mm bolus spacing. 78% patient satisfaction at 9 months.
Cheek Augmentation
Deep supraperiosteal placement with 22G cannula. Max 2ml per cheek. 82% volume retention at 12 months.
Medical Advisory Notice
Important: Clinical outcomes vary (±23%) based on individual tissue response and injection technique. Must be administered by certified dermatologists/plastic surgeons only. Contraindications include: active skin infections, bleeding disorders, and hypersensitivity to PCL/CMC components.
Post-treatment monitoring required for first 72 hours. Report any vascular compromise immediately. Not recommended for lip vermilion or glabellar regions.
